163 related articles for article (PubMed ID: 37482968)
1. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
Xie P; Tan SY; Li HF; Tang HD; Zhou JH
J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
[TBL] [Abstract][Full Text] [Related]
2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
3. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
[TBL] [Abstract][Full Text] [Related]
4. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway.
Chen X; An Y; Zhang Y; Xu D; Chen T; Yang Y; Chen W; Wu D; Zhang X
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):612-619. PubMed ID: 33764366
[TBL] [Abstract][Full Text] [Related]
5. Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer.
Mortazavi M; Moosavi F; Martini M; Giovannetti E; Firuzi O
Crit Rev Oncol Hematol; 2022 Aug; 176():103749. PubMed ID: 35728737
[TBL] [Abstract][Full Text] [Related]
6. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of laminin-5 gamma-2 promotes tumorigenesis of pancreatic ductal adenocarcinoma through EGFR/ERK1/2/AKT/mTOR cascade.
Kirtonia A; Pandey AK; Ramachandran B; Mishra DP; Dawson DW; Sethi G; Ganesan TS; Koeffler HP; Garg M
Cell Mol Life Sci; 2022 Jun; 79(7):362. PubMed ID: 35699794
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects.
Stanciu S; Ionita-Radu F; Stefani C; Miricescu D; Stanescu-Spinu II; Greabu M; Ripszky Totan A; Jinga M
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077529
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
10. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
Soares HP; Ni Y; Kisfalvi K; Sinnett-Smith J; Rozengurt E
PLoS One; 2013; 8(2):e57289. PubMed ID: 23437362
[TBL] [Abstract][Full Text] [Related]
11. Single-cell RNA sequencing reveals the mechanism of PI3K/AKT/mTOR signaling pathway activation in lung adenocarcinoma by KRAS mutation.
Xu L; Ding R; Song S; Liu J; Li J; Ju X; Ju B
J Gene Med; 2024 Jan; 26(1):e3658. PubMed ID: 38282149
[TBL] [Abstract][Full Text] [Related]
12. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
13. Saikosaponin d modulates the polarization of tumor-associated macrophages by deactivating the PI3K/AKT/mTOR pathway in murine models of pancreatic cancer.
Xu X; Cui L; Zhang L; Yang L; Zhuo Y; Li C
Int Immunopharmacol; 2023 Sep; 122():110579. PubMed ID: 37433245
[TBL] [Abstract][Full Text] [Related]
14. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Tian Z; Tan Y; Lin X; Su M; Pan L; Lin L; Ou G; Chen Y
Transl Res; 2023 May; 255():66-76. PubMed ID: 36400307
[TBL] [Abstract][Full Text] [Related]
16. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
17. AKT and mTOR expression in human pancreatic ductal adenocarcinoma. Relevance for tumor biology.
Handra-Luca A
Pathol Res Pract; 2023 Nov; 251():154878. PubMed ID: 37890271
[TBL] [Abstract][Full Text] [Related]
18. Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells.
Massoumi RL; Teper Y; Ako S; Ye L; Wang E; Hines OJ; Eibl G
Pancreas; 2021 Apr; 50(4):524-528. PubMed ID: 33939664
[TBL] [Abstract][Full Text] [Related]
19. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
[TBL] [Abstract][Full Text] [Related]
20. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
Yin F; Huang X; Xuan Y
Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]